ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Sarcopenia and Cardiovascular Diseases in Individuals With Diabetes or Prediabetes.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sarcopenia is a known risk factor for cardiovascular disease (CVD) in individuals with diabetes or prediabetes, but the impact of changes in sarcopenia status on CVD risk remains unclear. This study aimed to examine how changes in sarcopenia status between baseline and the second follow-up survey, conducted 2 years later, influence the risk of developing incident CVD. Incident CVD was identified based on self-reported physician diagnoses of heart disease, such as angina, myocardial infarction, heart failure, or stroke. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for potential confounders. The results showed that participants who progressed from non-sarcopenia to possible sarcopenia or sarcopenia had a higher risk of developing CVD. Their risk was significantly greater compared to those who remained non-sarcopenic (HR 1.37, 95% CI 1.08-1.73). Conversely, individuals who recovered from sarcopenia to non-sarcopenia or possible sarcopenia had a lower risk of CVD. Their risk was lower than those who remained sarcopenic (HR 0.40, 95% CI 0.20-0.82). Among individuals with possible sarcopenia at baseline, those who recovered to non-sarcopenia had a reduced CVD risk. This reduction was significant compared to those who remained in possible sarcopenia (HR 0.62, 95% CI 0.46-0.84). These findings suggest that changes in sarcopenia status have a significant impact on CVD risk, with worsening sarcopenia increasing the likelihood of CVD and recovery lowering the risk in individuals with diabetes or prediabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.